版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
IntroductionTreatmentofsymptomaticpatientswithHOCMaimstoreducesymptoms,improvefunctioncapacityandprovidebetterqualitylife.AimsdirectlytoreducethehypertrophiedinterventricularseptumwithconsecutiveexpansionoftheLVoutflowtractandreductionoftheLVoutflowtractgradientandimprovedistolicfunctionLV.Firstchoicedrugestreatment.
Atleast
10%
ofpatientswithmarkedoutflowtractobstructionhaveseveresymptoms,whichareunresponsivetomedicaltherapy.HOCMMyectomyDDD-PMICDPTSMAIntroductionTreatmentofsympt1HypertrophiccardiomyopathyEpidemiologicalcharacteristicsHypertrophiccardiomyopathyincidenceof0.2%(1:500),0.16%inourcountry
.Thevastmajorityofpatientswithnosymptoms,
25%ofoutflowtractobstructionoccurredonlyabout5-10%ofpatientswithdrugtreatmentsfailorcauseserioussideeffectsofdrugseffectivedose.Requiretreatmentorsurgicalinterventioninpatientstreatedwithonlyveryfewparts.
HypertrophiccardiomyopathyEp2PathophysiologicandclinicalcharacteristicsofHOCM
VentricularhypertrophyLeftventricularoutflowtractpressuregradientMyocardialischemia-anginapectoris.Arrhythmia-ventriculartachycardia,fibrillation.Clinicalmanifestations:dizziness,amaurosis,syncope,exertionalshortnessofbreath,anginapectoris,heartdisfunctionandsuddendeath.Generallyconsidered:moreseverehypertrophy,outflowtractobstructionneartheLVOTsit,themorehighertheobstructivepressuregradientwerethemoreobviousclinicalsymptomsandthegreaterthepotentialthreat.Pathophysiologicandclinical3ThenaturalcourseofoutflowtractobstructionLevel–anyages.thereisabigdifferenceinNaturalhistoryThenaturalcoursenotsure.Themorecardiachypertrophy,thehigherthepressuregradient,thegreatertheriskofsuddendeath.
Theoutflowtractpressuregradientoftheclinicalimportanceoftheissueremainscontroversial,butitisgenerallyconsideredanimportantclinicalprocessindicators.Nnualmortalityrateof2-4%,theincidenceof
suddendeath≤1%
Thenaturalcourseofoutflow4Thesymptoms
Whethertheobstructionproducedtheclinicalsymptoms?notonlywiththedegreeofoutflowtractobstructionandoutflowtractpressuregradient,aswellastheobstructionsite.Butalsowithventriculardiastolicfunctionandtheadequacyofvenousreturnisalsocloselyrelated.Increasetheheartbeforeandafterloadandmyocardialcontractilityoftencausenoticeableclinicalsymptoms.Therefore,itwillbecomemoreapparentafterexercise.Thepatientsshouldbetreatment.ThesymptomsWhethertheobs5Diastolicdysfunction
Allpatientshaddiastolicdysfunction–HowthepressuregradientandsymptomsAndtheextentanddistributionofthehypertrophyhasnothingtodo.Whethernormalorsmallventricularcavity,duetoincreasedheartweight,ventricularvolumereduction,myocardialfibrosis,leavingventricularstiffnessincreased,compliancedecreasedandcausedthediastolicfunctiondamage.Pulmonaryvenouspressureandend-diastolicpressure
wereincreasedandheartdisfunction.DiastolicdysfunctionAllpati6systolicfunctionSystolicfunctionisnormalorsupranormalinHCOMBothobstructionandnon-obstruction,Systolicdysfunctionoccursinsmallsubset(10-15%)
Resultofprogressiveimpairmentofsystolicfunction.Thistransformation:wallthinning,cavitydilation,andfibrosis,increasedmortality11%(annual)andriskofSCD.ConventionalUCG,M-mode,orEF,fractionalshorteningpreserveddespiteimpaimentlong-axisfunctionTissueDopplerimage(TD)-derivedsystolicvelocities:inthebasalinferoseptalandanterolateralwallroutinelyinallpatientsonsubsequentscans.systolicfunctionSystolicfunc7PTSMAindication(1)ClinicalindicationNodobutaminegradients(Drugs)CoronaryangiographyVerapamilRemoveballoonshouldbeemptyingalcoholoftheballooncatheterandstagnationinjectionalcoholOutflowtractobstructionsign
inEchocardiographSeptalthicknessHypertrophicCardiomyopathy
SurvivalAccordingtoOutflowTractGradientSystolicfunctionisnormalorsupranormalinHCOMMCEMorophologicindicationBeta-blockersasymmetricalseptalhypertrophy(ASH),2.Targetvesselsupplytonon-obstructionotherregionssuchas:papillarymuscle,freewall,etc.CONCLUSIONSBeta-blockersCONCLUSIONSCharacteristicsHypertrophiccardiomyopathyEpidemiologicalcharacteristicsMyocardialischemiaMyocardialischemia,thesymptomsofanginapectorisare:High-powersothatleftventricularmyocardialoxygenconsumptionincreased;Cardiaccontractionstrengthofoppressionthelargemyocardialcoronaryartery;Intramyocardialsmallcoronaryarterystenosisandintimalthickeningabnormalities,leadingtocardiachypertrophyandcoronaryarteryoxygenrequiredduetoanimbalanceofoxygensupply.PTSMAindication(1)Myocardia8Arrhythmiaandsuddendeath
HOCMofpatientswithabnormalmyocardialcellsandthearrangementofdisorderprovidesabasisforthearrhythmia.However,abnormalmyocardialarrangementandspontaneousarrhythmiasandventricularfibrillationthreshold,thepreciserelationshipisunclear.About25%ofpatientsmayhavenon-sustainedventriculartachycardia,thearrhythmiaissuddendeathofagoodpredictor,andnegativepredictiveaccuracyis97%.
ArrhythmiaandsuddendeathHO9RiskfactorsforsuddendeathHigh-risk:
1Suddendeathoccurredinasuccessfulrescue
2continuousmonomorphicventriculartachycardia
Clinicalriskfactors:
1non-sustainedventriculartachycardia
2movementabnormalbloodpressureresponse(≥25mmHg)
3unexplainedsyncope
4early-onsetfamilyhistoryofsuddendeath
5severeleftventricularhypertrophy>30mm
Riskfactorsforsuddendeath10ThepurposeofthetreatmentPTMSA
TreatmentofsymptomaticpatientswithHOCMThePTMSAtreatmentofHOCMisaobstructionbyblockingathesupplybloodofpartsoftheseptalhypertrophyofmyocardialandmyocardialinjuryintheregion,leadingtotheareaofmyocardialnecrosis,myocardialcontractilefunctiondisappeared,Widenedtheleftventricularoutflowtract,whileloweringtheoutflowtractobstructionandthecardiacoutputincrease.Andimproveclinicalsymptomsandhemodynamics.ThepurposeofthetreatmentP11PTSMAindication(1)ClinicalindicationSymptomaticpatientsDrugrefractoryseveresaideffectsmedicaltreatmentFunctionalclassIIIorIVFunctionalclassIIwithobjectivelimitationorriskfactorsRecurrentexercise-inducedsyncopesFailureofpriormyectomyorDDD-PMComorbitiywithincreasedsurgicalrisk.PTSMAindication(1)Clinical12PTSMAindication(2)HemodynamicindicationinsymptomaticpatientsThepressuregradientatrest>50mmHgor>100mmHgwithprovocation.In2008ESCmeeting,SeggewisethatLVgradient≧30mmHgatrestorProvocableLVgradient≧60mmHg.ValsalvaPostextrasystole.Nodobutaminegradients(Drugs)
(ThereisnoinformationthatreducetheLVOTpressuretoreducesuddendeath,buttheLVOT>30mmHgandincreasedriskofdeathdirectlyrelatedto,NewEnglJMed2003;348:295-303)
PTSMAindication(2)Hemodynam13HypertrophicCardiomyopathy
SurvivalAccordingtoOutflowTractGradientBJMaronetal;JAMA281:650-655,1999HypertrophicCardiomyopathy
S14PTSMAindication(3)MorophologicindicationEchocariography
SubaorrticSAM-associatedgradientMid-cavitarygradientCaution:papillarymuscleinvolvement:MCENoprolongedmitralleafletsCoronaryangiographysuitableseptalbranch.PTSMAindication(3)Moropholog15Outflowtractobstructionsign
inEchocardiographM-modeechocardiograminobstructivehypertrophiccardiomyopathyshowingsystolicanteriormotionofthemitralvalve(SAM)(arrowsindicatingseptumandmitralvalveleafletcontact)Outflowtractobstructionsign16
MorphologicofHOCMNewclassficationofHOCMMethods:theywereclassifiedinto4typesaccordingtotheechocardiographicresults:TypeI:localsubaorticobstructionofHOCM;TypeII:predominantinmidventicularobstruction;TypeIII:diffuseseptalhypertrophicobstructioninoutflowtractandmidventicularobstruction;TypeIV:multipositionhypertrophicobtruction.1.asymmetricalseptalhypertrophy(ASH),2.Idiopathichypertrophicsubaorticstenosis(IHSS),3.ApicalorJapaneseHCM.InthisformofnonobstructiveHCM,thethickestpartoftheleftventricleisatthetiporapexofthepump.4.theobstructionisnotintheoutflowtractbutinthemiddleoftheventricle.Atunnelleadsintoadilatedapicalportion,calledananeurysm,whichhasthinwalls.MorphologicofHOCM17OurclassficationinPTSMAOurtypingintheI-typeandMaronintheI-typingwasthesameassuitableforPTSMAtreatmentandMaron'sII-typeincludesthetypeIIandtype
IIIofourmodel,itissuitablePTSMAtreatment.Therefore,ourIV-typeclassificationisthefirstmadebyultrasoundimagingfeaturesofHOCM,accordingtoitscharacteristicsinlinewithPTSMAtreatment.OurclassficationinPTSMAO18ArrhythmiaandsuddendeathClinicalindicationSeptalAblationinHOCM
AcuteResults/AblationTechniquePathophysiologicandclinicalcharacteristicsofHOCMCharacteristics(post-PTSMA6months)Thevesselcannotthoroughorincompleteablation(remainingsmallerbranches),self-revascularization.SeptalthicknessCharacteristicsTransitorytrifascicularblocksoccurredatarateof52.(PG=80mmHg)DiltiazemThevesselcannotthoroughorincompleteablation(remainingsmallerbranches),self-revascularization.ResultsofPTSMASeptalthicknessHypertrophicCardiomyopathy
SurvivalAccordingtoOutflowTractGradientIncreasetheheartbeforeandafterloadandmyocardialcontractilityoftencausenoticeableclinicalsymptoms.Complicationsinourpatientsasymmetricalseptalhypertrophy(ASH),2.Mergeotherneedssurgeryheartdisease
Mitralvalveabnormalitiesandtheirownformofpapillarymusclesinvolvedintheformationofpressuregradient,ormitralvalveprolapseandregurgitation.PTSMAcontraindicationsTarget
vessel
Selectablationofregionalimportance,particularlyinthetargetvesselisnotclearwhotheseptalbranch
Thefirstseptalbranchofthesizeanddistributionaregreatvariation
20%ofpatientsfirstbranchwassuppliedthefreewallofrightventricle
40%ofpatientswithsubaorticofseptalisnotcompletelysupportedbythefirstseptalbranch
5%ofpatientscannotdeterminethetargetvesseloftheregionArrhythmiaandsuddendeathTar19Contrastechocardiographymethod
inthetargetvesse
choiceInjectionofasmallamountofdye(1-2ml)throughtheguidewirelumenoftheinflatedballooncatheterangiographicallyPriortoalcoholinjection1-2mlofechocontrastmediumisadministeredthroughthecentrallumenoftheballooncatheterunderUCG.determinesthesupplyareaofthetargetseptalbranch.Ensurethatnoareasinvolvingnon-obstructive,suchasthepapillarymusclesandventricularfreewallandotherparts.Contrastechocardiographymeth20Myocardial-Contrast-Echo
inHOCM
AvoidLADballooningExcludeLADleakageMyocardial-Contrast-Echoi21SeptalAblationinHOCM
Myocardial-Contrast-EchoLevovist
Intheintervalofcontrastagentinjectedintothebranchtoobservethedistributionofvascularcontr
Alcohol
ShadowSeptalAblationinHOCM
Myocar22
LevovistshadowLevovistshadow23Echosequence:SubaorticseptumastargetbregionintypicalSAM-associated,subaorticobstraction,(Ddottedline),EtestinjectionoftheechocontrastagentinballoonofthethefirstsetalbranchofaforwardbranchofpositionhighlightingbebasalhalfofseptumplusaRVpapillarymuscle(whitearrows).Aftersuper-selectiveballoonofotherbranchoffirstseptalbranch.Correctopacification.Echosequence:Subaorticseptu24MCEN=222NoMCEn=30PSeptalbranches(n)1.0±0.11.3±0.2<0.0001Alcohol(ml)2.9±0.93.9±2.4<0.0001Balloonsize(mm)1.9±0.42.4±0.2<0.0001CKmax(U/l)534±248745±420<0.001CK-MBmax(U/l)62±3096±62<0.0001H.Seggewissetal,49thScientificSessionsACC,2000SeptalAblationinHOCM
AcuteResults/AblationTechniqueMCENoMCEPSeptalbranches(n)125H.Seggewissetal,49thScientificSessionsACC,2000SeptalAblationinHOCM
AcuteResults/AblationTechniquep<0.05p<0.01H.Seggewissetal,49thScien26keysofTechnologyofPTSMA
Thekeytechnology:
identificationThepressuregradientatsubaorticandleftventricularidentificationsuitableoftargetseptalbranches.Mustbeinsertedtemporarypacemaker(topreventtheconductionblock).
Simultaneousmonitoringofaorticandleftventricularpressure.
Heparin(topreventcatheterinducedthrombosis).
AnalgesicGuidingcatheter:supportingflexibleandlowinjurySuitableOver-the-wireballooncatheterkeysofTechnologyofPTSMATh27ThekeysofTechnology
PTSMAIntraoperativeultrasoundmonitoringContrastechocardigraphyPaycloseattentiontothepressuregaugeunderfluoroscopy(observationballoonexpansionofstate).Injectionofalcoholdoseandspeeddeterminewhethershouldinjury(catheteroralcohol)andtheintervalbranchblock(necrosisstate)conditions1(withcomplications)or2septalbranches
ablationdidnotsignificantlyreducethepressure,andnoincreasealcoholdoseRemoveballoonshouldbeemptyingalcoholoftheballooncatheter
andstagnationinjectionalcoholThekeysofTechnologyPTSMAIn28(pre-PTSMA)Septalthickness(post-PTSMA3days)Mid-cavitarygradientTargetvesselsupplytonon-obstructionotherregionssuchas:papillarymuscle,freewall,etc.Priortoalcoholinjection1-2mlofechocontrastmediumisadministeredthroughthecentrallumenoftheballooncatheterunderUCG.Outflowtractobstructionsign
inEchocardiographAcutemitralregurgitationalsodidnotoccur.CONCLUSIONS43monthslater,90%ofthepatientsofthepressuregradientcompletelyeliminatedbyechocardiographic5mmandtoolong.MorphologicofHOCMTransitorytrifascicularblocksoccurredatarateof52.EchocariographyClinicalmanifestations:dizziness,amaurosis,syncope,exertionalshortnessofbreath,anginapectoris,heartdisfunctionandsuddendeath.Contrastechocardiographymethod
inthetargetvessechoiceClinicalindicationOutflowtractobstructionsign
inEchocardiographResultsofPTSMASystolicfunctionisnormalorsupranormalinHCOMSeptalthicknessContrastechocardigraphyAvoidLADballooningHypertrophiccardiomyopathyEpidemiologicalcharacteristicsContrastechocardiographycannotdeterminetargetvesselortheobstructionofregionalnosuitabletargetvessel.Doseofalcoholandspeed.(ThereisnoinformationthatreducetheLVOTpressuretoreducesuddendeath,buttheLVOT>30mmHgandincreasedriskofdeathdirectlyrelatedto,NewEnglJMed2003;348:295-303)FunctionalclassIIIorIVdeterminesthesupplyareaofthetargetseptalbranch.DDD-pacemaker:2-10%ResultsofPTSMAComplicationsinourpatientsApicalorJapaneseHCM.CharacteristicsThevesselcannotthoroughorincompleteablation(remainingsmallerbranches),self-revascularization.MorophologicindicationSystolicfunctionisnormalorsupranormalinHCOMThemorecardiachypertrophy,thehigherthepressuregradient,thegreatertheriskofsuddendeath.HypertrophicCardiomyopathy
SurvivalAccordingtoOutflowTractGradientClinicalindicationMustbeinsertedtemporarypacemaker(topreventtheconductionblock).(pre-PTSMA)A51-year-oldwoman’sLVOTgradientwasmonitoredcontinuouslyjustbeforetheballoonocclusion.(PG=80mmHg)LVAO(pre-PTSMA)Contrastechocardig29HerLVOTgradient10minutesafterseptalablation(PG=12mmHg)LVAOHerLVOTgradient10minutesa30A36-year-oldman’sLVOTgradienttestedbyDopplerechocardiographybeforePTSMA(PG=219mmHg)A36-year-oldman’sLVOTgradi31HisLVOTgradient6monthsafterPTSMA(PG=15mmHg)HisLVOTgradient6monthsaft32經(jīng)皮間隔支化學(xué)消融治療肥厚梗阻性心肌病英文課件(模板)33經(jīng)皮間隔支化學(xué)消融治療肥厚梗阻性心肌病英文課件(模板)34經(jīng)皮間隔支化學(xué)消融治療肥厚梗阻性心肌病英文課件(模板)35PG120mmHgbeforeprocedurePG120mmHgbeforeprocedure36PG=40mmHgafterinjectionof4.8mlalchoholPG=40mmHgafterinjectionof437GreatattentionEchocardiographyshowedventricularseptalhypertrophyover30mminHOCM,necessarytoperformeingPTSMAshouldbeverycautiousandcareful.Maybetherewereathickseptalbranch,andcontrolwide,and
collateral-richseptalbranchofsupport,treatmenthadahigherriskandimprovetheclinicalsymptomsandhemodynamicshavedifficulties,sosurgerymytomcemaybeabetterchoice.GreatattentionEchocardiog38Itisverybigseptalbranch>2.5mmandtoolong.ThereisquitedangertoPTMSAItisverybigseptalbranch>39PTSMAcontraindications
Nosignificantpressuregradientinhypertrophiccardiomyopathyorverydiffuseobstructive.
Mergeotherneedssurgeryheartdisease
Mitralvalveabnormalitiesandtheirownformofpapillarymusclesinvolvedintheformationofpressuregradient,ormitralvalveprolapseandregurgitation.
Contrastechocardiographycannotdeterminetargetvesselortheobstructionofregionalnosuitabletargetvessel.
Targetvesselsupplytonon-obstructionotherregionssuchas:papillarymuscle,freewall,etc.
NotsuitableOver-the-wireballoon.PTSMAcontraindicationsNosig40PTSMAcomplications(1)
Hospitalmortalityrate:1-2%DDD-pacemaker:2-10%
Myocardialinfarction
Reason:alcoholleakageintothepartsofinappropriate,collateralbranchopening,alcoholintotheinappropriatepartscauseno-reflow,LAD/LM/RCAinjury
Emergencysurgery
Reason:coronaryarteryinjury,acutemitralregurgitation(papillarymusclerupture)Bundlebranchblock:about50%andRBBB-basedPTSMAcomplications(1)Hosp41PTSMAcomplications(2)
HeightorIII°-AVB
Factors:
whetherthemethodofapplicationofmyocardialcontrastechocardiography.
Doseofalcoholandspeed.Leftanteriordescendingarterydissection,coronarythrombosis,ventricularfibrillationandventriculartachycardia,acutemitralregurgitation,rightventricularinfarction,leftventricularfreewallinfarction.PTSMAcomplications(2)Heig42PTSMAshortcomings
Injuryoftheleftcoronaryarteryrequiredemergencybypassorstent
Cannotenterthetargetseptalbranch
CannotdeterminethetargetbranchofsupportFormitralandpapillarymuscleanomaliesandabnormalseptalhypertrophythebestchoicethesurgery
Mitralvalveinjuryrequiredemergencysurgery.
PermanentconductionblockoccurstreatmentshouldbePMPTSMAshortcomingsInjuryoft43Theseptalbranchwithgoodcollateralcirculation.DiastolicdysfunctionBeta-blockersThevastmajorityofpatientswithnosymptoms,PTSMAcomplications(2)(post-PTSMA3days)PTSMAindication(3)EchocardiographicobservationsplaysanimportantroleinthatwillhelptofinalizedefinethechoiceofseptalablationandtheablationefficacyandreducerisksandLong-termfollow-upoftreatmentefficacy.ComplicationsinourpatientsPG120mmHgbeforeprocedureFunctionalclassIIwithobjectivelimitationorriskfactorsClinicalindicationPatients(n=171)EchocariographyGenerallyconsidered:moreseverehypertrophy,outflowtractobstructionneartheLVOTsit,themorehighertheobstructivepressuregradientwerethemoreobviousclinicalsymptomsandthegreaterthepotentialthreat.DiltiazemHOCMMyectomyFormitralandpapillarymuscleanomaliesandabnormalseptalhypertrophythebestchoicethesurgery59%)underwentpermanentpacemakerimplantationduetopermanentcompleteAVblock.VerapamilMyocardial-Contrast-EchoinHOCMHerLVOTgradient10minutesafterseptalablation(PG=12mmHg)PTSMAlimitations
Someyoungpatientstoreducethepressuregradienteffectisnotsatisfactory,thepossiblereasons:Theseptalbranchwithgoodcollateralcirculation.Thevesselcannotthorough
orincompleteablation(remainingsmallerbranches),self-revascularization.Ahigherdegreeofseptalhypertrophy,ahigherdegreeoffibrosis,Partsoftheseptalablationscarformationpoor.
Theseptalbranchwithgoodco44PTSMAin
FuwaiHospitalFromDec2000toMay2009,171patientsunderwentPTSMAinFuwaiHospital.Proceduresuccesswasachievedin141patients,successratewas82.6%.PTSMAin
FuwaiHospitalFrom45PatientCharacteristicsCharacteristicsPatients(n=171)Age(yrs)45.37±17.71Men/women122/49(71.35%/28.65%)SymptomsDyspnea93(54.39%)Angina73(42.69%)Syncope76(44.44%)NYHAfunctionalclass(II/III/IV)136(79.53%)/32(18.72%)/3(1.75%)Familyhistory42(24.6%)MedicationBeta-blockers106(62%)Verapamil52(30.4%)Diltiazem38(22.2%)Amiodanone13(7.6%)PatientCharacteristicsCharact46ResultsofPTSMAPTSMA(n=171)pSeptalthickness(pre-PTSMA)22.67±5.35mm
Septalthickness(post-PTSMA3days)20.68±4.61mmNSSeptalthickness(post-PTSMA6months)16.77±4.39mm<0.05LVOTPG(pre-PTSMA)97.58±38.23mmHgLVOTPG(post-PTSMA3days)52.36±35.7mmHg<0.001LVOTPG(post-PTSMA6months)47.26±38.62mmHg<0.001LADiameter(pre-PTSMA)43.78±7.33mm
LADiameter(post-PTSMA3days)42.41±7.52mmNSLADiameter(post-PTSMA6months)32.76±15.58mm<0.05ResultsofPTSMAPTSMA(n=171)p47ComplicationsinourpatientsIn-hospitaldeath
UptoMay2009,twopatientsdiedinthose171patients(1.17%)whounderwentPTSMAinFuwaiHospital.OnewasbecauseofalcoholleakagetotheLeftanteriordecendingartery,anotheroccurreddrug-inducedliverinjury.CompleteheartblockTransitorytrifascicularblocksoccurredatarateof
52.05%(89patients).
Onlyonepatient(0.59%)underwentpermanentpacemakerimplantationduetopermanentcompleteAVblock.ComplicationsinourpatientsI48ComplicationsinourpatientsOnepatient(0.59%)occurredventricularfibrillation,butherecoveredwellaftertheprocedure.Rightbundlebranchblockoccurredatarateof48.54%(83in171patients).NodissectionsoftheLMandLAD.NoemergencyCABGAcutemitralregurgitationalsodidnotoccur.ComplicationsinourpatientsO49Follow-upinourpatientsbyecho
Leftventricularoutflowtractpressuregradientwascontinuedtoasignificantdecreaseisanimportantfeature:Comparedwiththeacutephase,56%ofpatients3monthsrestingandstimulatethepressuregradientwillcontinuetodeclinefurther;Comparedwith3-monthperiod,43%ofpatientsoneyearthepressuregradientisstillfurtherreduced.After
3months40%ofpatientswithpressuregradientcompletelyreduced,ayearlaterthisvaluewaspromotedto62%.43monthslater,90%ofthepatientsofthepressuregradientcompletelyeliminatedbyechocardiographicFollow-upinourpatientsbye50CONCLUSIONSPTSMAisaneffectivenon-surgicalprocedureforsymptomaticpatientsandassociatedwithLVOTOinHOCMbecauseofitslowriskanditssignificanthemodynamicandsymptomaticimprovement.Ablationareashouldbeappropriate,assmallaspossible,toavoidalargescarformation.EchocardiographicobservationsplaysanimportantroleinthatwillhelptofinalizedefinethechoiceofseptalablationandtheablationefficacyandreducerisksandLong-termfollow-upoftreatmentefficacy
.CONCLUSIONSPTSMAisaneffecti51Advice
Whohavenosymptomsormildsymptomsofthepatient,determinednottoconsiderthelinetoreduceoutflowtractobstructionofanytherapeuticinterventionmeasures(includingsurgicalandinterventionaltreatment)!!!AdviceWhohavenosymptoms52經(jīng)皮間隔支化學(xué)消融治療肥厚梗阻性心肌病英文課件(模板)53PTSMAindication(1)ClinicalindicationSymptomaticpatientsDrugrefractoryseveresaideffectsmedicaltreatmentFunctionalclassIIIorIVFunctionalclassIIwithobjectivelimitationorriskfactorsRecurrentexercise-inducedsyncopesFailureofpriormyectomyorDDD-PMComorbitiywithincreasedsurgicalrisk.PTSMAindication(1)Clinical54PTSMAindication(2)HemodynamicindicationinsymptomaticpatientsThepressuregradientatrest>50mmHgor>100mmHgwithprovocation.In2008ESCmeeting,SeggewisethatLVgradient≧30mmHgatrestorProvocableLVgradient≧60mmHg.ValsalvaPostextrasystole.Nodobutaminegradients(Drugs)
(ThereisnoinformationthatreducetheLVOTpressuretoreducesuddendeath,buttheLVOT>30mmHgandincreasedriskofdeathdirectlyrelatedto,NewEnglJMed2003;348:295-303)
PTSMAindication(2)Hemodynam55HypertrophicCardiomyopathy
SurvivalAccordingtoOutflowTractGradientBJMaronetal;JAMA281:650-655,1999HypertrophicCardiomyopathy
S56A36-year-oldman’sLVOTgradienttestedbyDopplerechocardiographybeforePTSMA(PG=219mmHg)A36-year-oldman’sLVOTgradi57PTSMAcontraindications
Nosignificantpressuregradientinhypertrophiccardiomyopathyorverydiffuseobstructive.
Mergeotherneedssurgeryheartdisease
Mitralvalveabnormalitiesandtheirownformofpapillarymusclesinvolvedintheformationofpressuregradient,ormitralvalveprolapseandregu
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 描繪春天美麗的風(fēng)景
- 北師大初一英語(yǔ)下冊(cè)學(xué)習(xí)總結(jié)指導(dǎo)
- 蘇教版牛郎織女教學(xué)方案
- 中考生物蘇教版知識(shí)點(diǎn)詳解與解析
- 赤壁懷古念奴嬌的豪情壯志
- 蘇教版大禹治水課件提升歷史教學(xué)的品質(zhì)
- 深情厚意朱自清的背影
- 蘇教版三年級(jí)英語(yǔ)教學(xué)法
- 高中英語(yǔ)選修八詞匯表拓展學(xué)習(xí)
- 珍珠泉之美人教版課件欣賞
- 2023刑事訴訟法全文
- 統(tǒng)編版2024道德與法治七年級(jí)上冊(cè) 教材單元思考與行動(dòng)解答示例
- 幼兒園 中班數(shù)學(xué)《學(xué)習(xí)按物體長(zhǎng)短、高矮、粗細(xì)、排序》
- 血液透析患者的容量管理
- 慢性阻塞性肺疾病案例分析護(hù)理
- 航天禁(限)用工藝目錄(2021版)-發(fā)文稿(公開)
- 產(chǎn)品設(shè)計(jì)研發(fā)能力分析報(bào)告
- 勞務(wù)服務(wù)實(shí)施方案
- 婦科宮腔占位護(hù)理查房
- 乘用車用保險(xiǎn)杠編輯說(shuō)明
- 供應(yīng)商CSR風(fēng)險(xiǎn)識(shí)別評(píng)定表(Foxlink富港中英文版)+自評(píng)回復(fù)模板OK
評(píng)論
0/150
提交評(píng)論